Why the study?
Arrhythmias significantly contribute to morbidity and mortality in cardiomyopathies and antiarrhythmic management is challenging, warranting an electrophysiological perspective on the new ESC cardiomyopathy guidelines.
This overview summarizes the new ESC cardiomyopathy guidelines for electrophysiologists, highlighting phenotype-based classification, multimodal imaging, genetic testing, and updated arrhythmia management strategies.
Answers are grounded in this paper and cite their sources.
May inform updated ICD decisions in cardiomyopathies; leaves open prospective validation of phenotype-based and genetic strategies.
Electrocardiographic findings and arrhythmias are common in cardiomyopathies. Both may be an early indication of a specific diagnosis or may occur due to myocardial fibrosis and/or reduced contractility. Brady- and tachyarrhythmias significantly contribute to increased morbidity and mortality in patients with cardiomyopathies. Antiarrhythmic therapy including risk stratification is often challenging and plays a major role for these patients. Thus, an "electrophysiological" perspective on guidelines on cardiomyopathies may be warranted. As the European Society of Cardiology (ESC) has recently published a new guideline for the management of cardiomyopathies, this overview aims to present key messages of these guidelines. Innovations include a new phenotype-based classification system with emphasis on a multimodal imaging approach for diagnosis and risk stratification. The guideline includes detailed chapters on dilated and hypertrophic cardiomyopathy and their phenocopies, arrhythmogenic right ventricular cardiomyopathy, and restrictive cardiomyopathy as well as syndromic and metabolic cardiomyopathies. Patient pathways guide clinicians from the initial presentation to diagnosis. The role of cardiovascular magnetic resonance imaging and genetic testing during diagnostic work-up is stressed. Concepts of rhythm and rate control for atrial fibrillation have led to new recommendations, and the role of defibrillator therapy in primary prevention is discussed in detail. Whilst providing general guidelines for management, the primary objective of the guideline is to ascertain the disease etiology and disease-specific, individualized management.
No takes yet. Share an insight, caveat, or question.
Korthals et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: